相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In Vitro and In Vivo Properties of BAL30376, a β-Lactam and Dual β-Lactamase Inhibitor Combination with Enhanced Activity against Gram-Negative Bacilli That Express Multiple β-Lactamases
Malcolm G. P. Page et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
P. R. S. Lagace-Wiens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Design and synthesis of potent Gram-negative specific LpxC inhibitors
U. Faruk Mansoor et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae
Emilia Titelman et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104
Daniel Curcio
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2011)
Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates
D. M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City
David Landman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain
Benjamin A. Rogers et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii
Thomas A. Russo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?
Patrice Nordmann et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007
Kazunori Gomi et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2011)
Doripenem: A new carbapenem antibiotic
Elias B. Chahine et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
Hydrolysis and Inhibition Profiles of beta-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem
Anne Marie Queenan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Potentiation of Carbapenems with ME1071, a Novel Metallo-β-Lactamase Inhibitor, against Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Clinical Isolates
Yoshikazu Ishii et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Comparative In Vitro Activity Profiles of Novel Bis-Indole Antibacterials against Gram-Positive and Gram-Negative Clinical Isolates
Michelle M. Butler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli
Malcolm G. P. Page et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
A Multicenter, Randomized Controlled Clinical Study on Biapenem and Imipenem/Cilastatin Injection in the Treatment of Respiratory and Urinary Tract Infections
Bei Jia et al.
CHEMOTHERAPY (2010)
The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
David N. Gilbert et al.
CLINICAL INFECTIOUS DISEASES (2010)
Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin-Structure Infection
G. Ralph Corey et al.
CLINICAL INFECTIOUS DISEASES (2010)
Pharmacodynamic Modeling of Intravenous Antibiotics Against Gram-Negative Bacteria Collected in the United States
Pornpan Koomanachai et al.
CLINICAL THERAPEUTICS (2010)
Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit
Lisa L. Maragakis
CRITICAL CARE MEDICINE (2010)
Resistance to polymyxins: Mechanisms, frequency and treatment options
Matthew E. Falagas et al.
DRUG RESISTANCE UPDATES (2010)
Current Challenges in Antimicrobial Chemotherapy Focus on beta-Lactamase Inhibition
Carine Bebrone et al.
DRUGS (2010)
Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates
C. Betriu et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2010)
Ceftaroline for complicated skin and skin-structure infections
Esteban C. Nannini et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
New aminoglycoside antibiotics
Paola Dozzo et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
The Antibiotic Development Pipeline for Multidrug-Resistant Gram-Negative Bacilli: Current and Future Landscapes
George H. Talbot
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Current Epidemiology of Multidrug-Resistant Gram-Negative Bacilli in the United States
Alexander J. Kallen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Relation between the Antimicrobial Susceptibility of Clinical Isolates of Pseudomonas aeruginosa from Respiratory Specimens and Antimicrobial Use Density (AUD) from 2005 through 2008
Yasutsugu Fukushima et al.
INTERNAL MEDICINE (2010)
Emerging carbapenemases: a global perspective
Timothy R. Walsh
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens
Yvonne Pfeifer et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2010)
Resistance development profiling of piperacillin in combination with the novel β-lactamase inhibitor BLI-489
Alexey Ruzin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Activity of BAL30376 (monobactam BAL19764+BAL29880+clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
David Landman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae
S. Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Extended-Spectrum-beta-Lactamase, AmpC, and Carbapenemase Issues
Kenneth S. Thomson
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy et al.
LANCET INFECTIOUS DISEASES (2010)
Promiscuous DNA: horizontal transfer of transposable elements and why it matters for eukaryotic evolution
Sarah Schaack et al.
TRENDS IN ECOLOGY & EVOLUTION (2010)
Antimicrobial Peptides: Primeval Molecules or Future Drugs?
Brian M. Peters et al.
PLOS PATHOGENS (2010)
Extended-spectrum β-lactamases in Gram Negative Bacteria
Deepti Rawat et al.
JOURNAL OF GLOBAL INFECTIOUS DISEASES (2010)
In Vitro Activity of LK-157, a Novel Tricyclic Carbapenem As Broad-Spectrum β-Lactamase Inhibitor
Susanne Paukner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Efficacy of Piperacillin Combined with the Penem β-Lactamase Inhibitor BLI-489 in Murine Models of Systemic Infection
Peter J. Petersen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including beta-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
Celine Vidaillac et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Bad Bugs, No Drugs: No ESCAPE Revisited
Lance R. Peterson
CLINICAL INFECTIOUS DISEASES (2009)
The Spread of Klebsiella pneumoniae Carbapenemases: A Tale of Strains, Plasmids, and Transposons
L. Silvia Munoz-Price et al.
CLINICAL INFECTIOUS DISEASES (2009)
Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
Philip D. Lister et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive update
M. Shahid et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2009)
Current Status of Newer Carbapenems
Matteo Bassetti et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Prospects for the next anti-Pseudomonas drug
Malcolm G. P. Page et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Ceftobiprole: a new broad spectrum cephalosporin
Ali El Solh
EXPERT OPINION ON PHARMACOTHERAPY (2009)
An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity
Mark Baer et al.
INFECTION AND IMMUNITY (2009)
Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?
Helen C. Maltezou
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia
Ian Morrissey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens
Garyphallia Poulakou et al.
JOURNAL OF INFECTION (2009)
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Patrice Nordmann et al.
LANCET INFECTIOUS DISEASES (2009)
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa
Tetsufumi Koga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2008)
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections
Gary J. Noel et al.
CLINICAL INFECTIOUS DISEASES (2008)
Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial
A. C. Rodloff et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study
Jean Chastre et al.
CRITICAL CARE MEDICINE (2008)
Novel beta-lactam antibiotics and inhibitor combinations
Matteo Bassetti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp K04-0144 - I. Taxonomy, fermentation, isolation and structural elucidation
Atsushi Fukumoto et al.
JOURNAL OF ANTIBIOTICS (2008)
Current concepts: Acinetobacter infection
L. Silvia Munoz-Price et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinical and economic impact of common multidrug-resistant gram-negative bacilli
Christian G. Giske et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Aminoglycosides versus bacteria - a description of the action, resistance mechanism, and nosocomial battleground
Shazi Shakil et al.
JOURNAL OF BIOMEDICAL SCIENCE (2008)
Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia:: a systematic review and meta-analysis
Mitchell J. Schwaber et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae
David Keeney et al.
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE (2007)
Evolution of β-lactam biosynthesis genes and recruitment of trans-acting factors
AA Brakhage et al.
PHYTOCHEMISTRY (2005)
Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release
S Eschenburg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors
WJ Weiss et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacodynamics of ceftazidime plus the serine β-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 β-lactamases
KE Bowker et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms
CE Jamieson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Fluoroquinolones: Action and resistance
K Drlica et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2003)
Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli
S Kobayashi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
分享论文
